Patents by Inventor Peter James Dunn

Peter James Dunn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12055766
    Abstract: A system includes a housing that has a front panel; a substrate that is positioned at a distance from the front panel, in which a data processor is mounted on the substrate; and a pluggable module. The pluggable module includes a co-packaged optical module, at least one first optical connector, a first fiber optic cable that is optically coupled between the co-packaged optical module and the first optical connector, and a fiber guide that is positioned between the co-packaged optical module and the first optical connector and provides mechanical support for the co-packaged optical module and the first optical connector. The co-packaged optical module is configured to receive optical signals from the first optical connector, generate electrical signals based on the received optical signals, and transmit the electrical signals to the data processor.
    Type: Grant
    Filed: March 14, 2023
    Date of Patent: August 6, 2024
    Assignee: Nubis Communications, Inc.
    Inventors: Peter James Pupalaikis, Ron Zhang, Brett Michael Dunn Sawyer, Clinton Randy Giles, Peter Johannes Winzer
  • Publication number: 20080167367
    Abstract: A stable solid hydrate of a muscarinic receptor antagonist is useful in the treatment of irritable bowel syndrome, diverticular disease, oesophageal achalasia, chronic obstructive airways disease, over active bladder (including symptoms of incontinence, urge and frequency), urinary incontinence, neurogenic urinary urgency or pollakiuria, treatment of bladder functional disorder, urinary leakage, painful or difficult urination caused by neurogenic bladder, spastic or hypertonic bladder, dysfunctional bladder syndrome, gastrointestinal disorders including gastrointestinal hyperactivity, and relaxing effect on intestinal smooth muscle cells.
    Type: Application
    Filed: March 17, 2008
    Publication date: July 10, 2008
    Inventors: Peter James Dunn, John George Matthews, Trevor Jack Newbury, Garry O'Connor
  • Patent number: 7005520
    Abstract: There is provided a process for the production a compound of general formula I: wherein A, R1, R2, R3 and R4 have meanings given in the description, which process comprises the reaction of a compound of formula II, wherein Rx is a group substitutable by an aminopyrazole, with a compound of general formula III
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: February 28, 2006
    Assignee: Pfizer Inc.
    Inventors: Peter James Dunn, Catherine Dunne
  • Patent number: 6930188
    Abstract: A stable solid hydrate of a muscarinic receptor antagonist is useful in the treatment of irritable bowel syndrome, diverticular disease, oesophageal achalasia, chronic obstructive airways disease, over active bladder (including symptoms of incontinence, urge and frequency), urinary incontinence, neurogenic urinary urgency or pollakiuria, treatment of bladder functional disorder, urinary leakage, painful or difficult urination caused by neurogenic bladder, spastic or hypertonic bladder, dysfunctional bladder syndrome, gastrointestinal disorders including gastrointestinal hyperactivity, and relaxing effect on intestinal smooth muscle cells.
    Type: Grant
    Filed: March 25, 2003
    Date of Patent: August 16, 2005
    Assignee: Novartis International Pharmaceutical, Ltd.
    Inventors: Peter James Dunn, John George Matthews, Trevor Jack Newbury, Garry O'Connor
  • Publication number: 20040106796
    Abstract: There is provided a process for the production a compound of general formula I: 1
    Type: Application
    Filed: November 25, 2003
    Publication date: June 3, 2004
    Applicant: Pfizer Inc
    Inventors: Peter James Dunn, Catherine Dunne
  • Patent number: 6667398
    Abstract: There is provided a process for the production a compound of general formula I: wherein A, R1, R2, R3 and R4 have meanings given in the description, which process comprises the reaction of a compound of formula II, wherein Rx is a group substitutable by an aminopyrazole, with a compound of general formula III
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: December 23, 2003
    Assignee: Pfizer Inc
    Inventors: Peter James Dunn, Catherine Dunne
  • Patent number: 6653339
    Abstract: The present invention is directed to a a method for the treatment of irritable bowel syndrome comprising the multiple daily pulse dosing of an immediate release formulation of the anti-muscarinic darifenacin. Dosing two or three times a day is particularly preferred.
    Type: Grant
    Filed: August 13, 2002
    Date of Patent: November 25, 2003
    Assignee: Pfizer Inc.
    Inventors: Peter James Dunn, Michael John Humphrey, Paul Quinn
  • Publication number: 20030191176
    Abstract: A stable solid hydrate of a muscarinic receptor antagonist is useful in the treatment of irritable bowel syndrome, diverticular disease, oesophageal achalasia, chronic obstructive airways disease, over active bladder (including symptoms of incontinence, urge and frequency), urinary incontinence, neurogenic urinary urgency or pollakiuria, treatment of bladder functional disorder, urinary leakage, painful or difficult urination caused by neurogenic bladder, spastic or hypertonic bladder, dysfunctional bladder syndrome, gastrointestinal disorders including gastrointestinal hyperactivity, and relaxing effect on intestinal smooth muscle cells.
    Type: Application
    Filed: March 25, 2003
    Publication date: October 9, 2003
    Applicant: Pfizer Inc.
    Inventors: Peter James Dunn, John George Matthews, Trevor Jack Newbury, Garry O'Connor
  • Publication number: 20030158206
    Abstract: Intranasal formulations of sildenafil mesylate for the treatment of male erectile dysfunction or female sexual disorders.
    Type: Application
    Filed: March 14, 2003
    Publication date: August 21, 2003
    Inventors: Anne Billotte, Peter James Dunn, Brian Thomas Henry, Peter Vallance Marshall, Joanna Jayne Woods
  • Publication number: 20030114356
    Abstract: The present invention is directed to a a method for the treatment of irritable bowel syndrome comprising the multiple daily pulse dosing of an immediate release formulation of the anti-muscarinic darifenacin. Dosing two or three times a day is particularly preferred.
    Type: Application
    Filed: August 13, 2002
    Publication date: June 19, 2003
    Inventors: Peter James Dunn, Michael John Humphrey, Paul Quinn
  • Publication number: 20030069422
    Abstract: A process is provided for the preparation of a compound of formulae (IA) (sidenafil) and (IB) 1
    Type: Application
    Filed: September 23, 2002
    Publication date: April 10, 2003
    Inventors: Peter James Dunn, Philip Charles Levett
  • Publication number: 20020040139
    Abstract: Intranasal formulations of sildenafil mesylate for the treatment of male erectile dysfunction or female sexual disorders.
    Type: Application
    Filed: June 18, 1999
    Publication date: April 4, 2002
    Inventors: ANNE BILLOTTE, PETER JAMES DUNN, BRIAN THOMAS HENRY
  • Publication number: 20020013464
    Abstract: There is provided a process for the production a compound of general formula I: 1
    Type: Application
    Filed: June 21, 2001
    Publication date: January 31, 2002
    Inventors: Peter James Dunn, Catherine Dunne
  • Publication number: 20010009962
    Abstract: A process is provided for the preparation of a compound of formulae (IA) (sidenafil) and (IB) 1
    Type: Application
    Filed: January 16, 2001
    Publication date: July 26, 2001
    Inventors: Peter James Dunn, Philip Charles Levett
  • Patent number: 6207829
    Abstract: A process is provided for the preparation of a compound of formulae (IA) (sidenafil) and (IB) comprising reacting a compound of formula (IIA) and (IIB) respectively in the presence of —OR, wherein R in the case of formation of compound (IA) is CH2CH3 and R in the case of formation of compound (IB) is CH2CH2CH3, where X is a leaving group:
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: March 27, 2001
    Assignee: Pfizer Inc.
    Inventors: Peter James Dunn, Philip Charles Levett
  • Patent number: 6180665
    Abstract: The present invention relates to a crystalline, &agr;-polymorphic form of a compound of formula (I) and to processes for the preparation of, to intermediates used in the preparation of, to compositions containing and to uses of, the &agr;-polymorphic form.
    Type: Grant
    Filed: May 28, 1996
    Date of Patent: January 30, 2001
    Assignee: Pfizer Inc.
    Inventors: Peter James Dunn, Michael Leslie Hughes
  • Patent number: 6066735
    Abstract: A process for the preparation of a compound of formula (I): ##STR1## which comprises cyclization of a compound of formula (II): ##STR2##
    Type: Grant
    Filed: July 23, 1999
    Date of Patent: May 23, 2000
    Assignee: Pfizer Inc.
    Inventors: Peter James Dunn, Albert Shaw Wood
  • Patent number: 5955611
    Abstract: A process for the preparation of a compound of formula (I): ##STR1## which comprises cyclization of a compound of formula (II): ##STR2##
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: September 21, 1999
    Assignee: Pfizer Inc.
    Inventors: Peter James Dunn, Albert Shaw Wood